ERBB2 and colorectal carcinoma: Similarly, in two previous studies by Gong53 and EI-Deiry54, HER2 amplification was identified using NGS in patients with CRC, and the reported positive rates were 5.1% (7/138) and 5.7% (94/1653), respectively.